We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3,866.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDPH
RNS Number : 7504Z
Dechra Pharmaceuticals PLC
15 January 2024
15 January 2024
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Dechra Pharmaceuticals PLC announces that following the Court sanctioning the Scheme at the Sanction Hearing on 12 January 2024, the following PDMRs acquired ordinary shares of 1p each in the Company pursuant to awards granted to them under the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP), the Deferred Bonus Plan 2021 and the Global Save As You Earn Plan 2018 (SAYE) as detailed in the tables below. All shares were subject to the Cash Offer of the Company at GBP38.75 per share:
Long Term Incentive Plan, SAYE and Deferred Bonus Plan
Name Capacity Date of Grant Award Cost Shares Acquired & Sold 22 September Ian Page Director 2020* Qualifying LTIP* Nil 5,372 22 September Ian Page Director 2020* Qualifying CSOP GBP32.37 155 16 September Ian Page Director 2021 LTIP** Nil 18,551 9 September Ian Page Director 2022 LTIP ** Nil 20,193 20 September Deferred Bonus Ian Page Director 2022 Plan Nil 3,580 19 October Ian Page Director 2020 SAYE GBP28.68 627 22 September Paul Sandland Director 2020* LTIP* Nil 2,335 16 September Paul Sandland Director 2021 LTIP** Nil 8,600 9 September Paul Sandland Director 2022 Qualifying LTIP** Nil 9,983 9 September Qualifying CSOP Paul Sandland Director 2022 +/- GBP31.99 227 20 September Deferred Bonus Paul Sandland Director 2022 Plan Nil 2,293 19 October Paul Sandland Director 2020 SAYE GBP28.68 627
*The vesting of the awards was subject to the achievement of performance conditions which were satisfied to the extent that the awards vested at 16.4%.
Ian Page exercised the linked tax qualifying option at an exercise price of GBP32.37 as part of his LTIP award. 25 nil cost options were forfeited to the value of that gain.
** Both the EPS and ROCE performance conditions for LTIP awards granted in 2021 and 2022 were deemed to have been met as detailed in the Co-Operation Agreement between the Company and Freya Bidco Limited. The TSR performance conditions was measured for both awards. The awards taking into account all of the performance conditions vested at 90.8% for the 2021 grant and 100% for the 2022 grant. Both awards were pro rata for time.
+/- Paul Sandland exercised the linked tax qualifying option at an exercise price of GBP31.99 as part of his LTIP award. 39 nil cost options were forfeited to the value of that gain.
Deferred Bonus Plan 2021 (Cash Settled)
Ian Page and Paul Sandland were granted on 18 October 2023, 1,080 and 715 awards respectively under the Deferred Bonus Plan 2021. These were cash settled in accordance with the Co-Operation Agreement between the Company and Freya Bidco Limited.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.
Notification of Dealing Forms
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Ian Page ---------------------------------- ---------------------------------------- 2. Reason for the notification ---------------------------------------------------------------------------- a) Position/status Director/PDMR ---------------------------------- ---------------------------------------- b) Initial notification/ Initial Notification amendment ---------------------------------- ---------------------------------------- 3. Details of the Issuer ---------------------------------------------------------------------------- a) Name Dechra Pharmaceuticals PLC ---------------------------------- ---------------------------------------- b) LEI code 213800J4UVB5OWG8VX82 ---------------------------------- ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------------------- a) Description of Ordinary Shares of 1 pence each the financial instrument ISIN: GB0009633180 Identification code ---------------------------------- ---------------------------------------- b) Nature of the Acquisition of shares pursuant to the transaction Company's Long Term Incentive Plan ---------------------------------- ---------------------------------------- c) Price(s) and volumes(s) Price(s) Volume(s) GBPNil Cost 5,372 ---------------------------------- ---------------------- ---------------- d) Aggregated information * Aggregate volume N/A * Price * Total ---------------------------------- ---------------------------------------- e) Date of the transaction 2024.01.15 ---------------------------------- ---------------------------------------- f) Place of the transaction Outside a trading venue ---------------------------------- ---------------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Ian Page ------------------------------------ ---------------------------------------- 2. Reason for the notification ------------------------------------------------------------------------------ a) Position/status Director/PDMR ------------------------------------ ---------------------------------------- b) Initial notification/ Initial Notification amendment ------------------------------------ ---------------------------------------- 3. Details of the Issuer ------------------------------------------------------------------------------ a) Name Dechra Pharmaceuticals PLC ------------------------------------ ---------------------------------------- b) LEI code 213800J4UVB5OWG8VX82 ------------------------------------ ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------------------ a) Description of Ordinary Shares of 1 pence each the financial instrument ISIN: GB0009633180 Identification code ------------------------------------ ---------------------------------------- b) Nature of the Acquisition of shares pursuant to the transaction Company's Long Term Incentive Plan ------------------------------------ ---------------------------------------- c) Price(s) and volumes(s) Price(s) Volume(s) GBP32.37 155 ------------------------------------ ------------------- ------------------- d) Aggregated information * Aggregate volume 155 GBP32.37 * Price GBP5,017.35 * Total ------------------------------------ ---------------------------------------- e) Date of the transaction 2024.01.15 ------------------------------------ ---------------------------------------- f) Place of the transaction Outside a trading venue ------------------------------------ ---------------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Ian Page ---------------------------------- ---------------------------------------- 2. Reason for the notification ---------------------------------------------------------------------------- a) Position/status Director/PDMR ---------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification amendment ---------------------------------- ---------------------------------------- 3. Details of the Issuer ---------------------------------------------------------------------------- a) Name Dechra Pharmaceuticals PLC ---------------------------------- ---------------------------------------- b) LEI code 213800J4UVB5OWG8VX82 ---------------------------------- ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------------------- a) Description of Ordinary Shares of 1 pence each the financial instrument ISIN: GB0009633180 Identification code ---------------------------------- ---------------------------------------- b) Nature of the Acquisition of shares pursuant to the transaction Company's Long Term Incentive Plan ---------------------------------- ---------------------------------------- c) Price(s) and volumes(s) Price(s) Volume(s) GBPNil Cost 18,551 ---------------------------------- ---------------------- ---------------- d) Aggregated information * Aggregate volume N/A * Price * Total ---------------------------------- ---------------------------------------- e) Date of the transaction 2024.01.15 ---------------------------------- ---------------------------------------- f) Place of the transaction Outside a trading venue ---------------------------------- ---------------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Ian Page ---------------------------------- ---------------------------------------- 2. Reason for the notification ---------------------------------------------------------------------------- a) Position/status Director/PDMR ---------------------------------- ---------------------------------------- b) Initial notification/ Initial Notification amendment ---------------------------------- ---------------------------------------- 3. Details of the Issuer ---------------------------------------------------------------------------- a) Name Dechra Pharmaceuticals PLC ---------------------------------- ---------------------------------------- b) LEI code 213800J4UVB5OWG8VX82 ---------------------------------- ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------------------- a) Description of Ordinary Shares of 1 pence each the financial instrument ISIN: GB0009633180 Identification code ---------------------------------- ---------------------------------------- b) Nature of the Acquisition of shares pursuant to the transaction Company's Long Term Incentive Plan ---------------------------------- ---------------------------------------- c) Price(s) and volumes(s) Price(s) Volume(s) GBPNil Cost 20,193 ---------------------------------- ---------------------- ---------------- d) Aggregated information * Aggregate volume N/A * Price * Total ---------------------------------- ---------------------------------------- e) Date of the transaction 2024.01.15 ---------------------------------- ---------------------------------------- f) Place of the transaction Outside a trading venue ---------------------------------- ---------------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Ian Page ---------------------------------- ---------------------------------------- 2. Reason for the notification ---------------------------------------------------------------------------- a) Position/status Director/PDMR ---------------------------------- ---------------------------------------- b) Initial notification/ Initial Notification amendment ---------------------------------- ---------------------------------------- 3. Details of the Issuer ---------------------------------------------------------------------------- a) Name Dechra Pharmaceuticals PLC ---------------------------------- ---------------------------------------- b) LEI code 213800J4UVB5OWG8VX82 ---------------------------------- ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------------------- a) Description of Ordinary Shares of 1 pence each the financial instrument ISIN: GB0009633180 Identification code ---------------------------------- ---------------------------------------- b) Nature of the Acquisition of shares pursuant to the transaction Company's Deferred Bonus Plan ---------------------------------- ---------------------------------------- c) Price(s) and volumes(s) Price(s) Volume(s) GBPNil Cost 3,580 ---------------------------------- ---------------------- ---------------- d) Aggregated information * Aggregate volume N/A * Price * Total ---------------------------------- ---------------------------------------- e) Date of the transaction 2024.01.15 ---------------------------------- ---------------------------------------- f) Place of the transaction Outside a trading venue ---------------------------------- ---------------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Ian Page ------------------------------------ ------------------------------------------ 2. Reason for the notification -------------------------------------------------------------------------------- a) Position/status Director/PDMR ------------------------------------ ------------------------------------------ b) Initial notification/ Initial Notification amendment ------------------------------------ ------------------------------------------ 3. Details of the Issuer -------------------------------------------------------------------------------- a) Name Dechra Pharmaceuticals PLC ------------------------------------ ------------------------------------------ b) LEI code 213800J4UVB5OWG8VX82 ------------------------------------ ------------------------------------------ 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted -------------------------------------------------------------------------------- a) Description of Ordinary Shares of 1 pence each the financial instrument ISIN: GB0009633180 Identification code ------------------------------------ ------------------------------------------ b) Nature of the Acquisition of shares pursuant to the transaction Company's Global Save As You Earn Plan ------------------------------------ ------------------------------------------ c) Price(s) and volumes(s) Price(s) Volume(s) GBP28.68 627 ------------------------------------ -------------------- -------------------- d) Aggregated information * Aggregate volume 627 GBP28.68 * Price GBP17,982.36 * Total
------------------------------------ ------------------------------------------ e) Date of the transaction 2024.01.15 ------------------------------------ ------------------------------------------ f) Place of the transaction Outside a trading venue ------------------------------------ ------------------------------------------ 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Paul Sandland ---------------------------------- ---------------------------------------- 2. Reason for the notification ---------------------------------------------------------------------------- a) Position/status Director/PDMR ---------------------------------- ---------------------------------------- b) Initial notification/ Initial Notification amendment ---------------------------------- ---------------------------------------- 3. Details of the Issuer ---------------------------------------------------------------------------- a) Name Dechra Pharmaceuticals PLC ---------------------------------- ---------------------------------------- b) LEI code 213800J4UVB5OWG8VX82 ---------------------------------- ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------------------- a) Description of Ordinary Shares of 1 pence each the financial instrument ISIN: GB0009633180 Identification code ---------------------------------- ---------------------------------------- b) Nature of the Acquisition of shares pursuant to the transaction Company's Long Term Incentive Plan ---------------------------------- ---------------------------------------- c) Price(s) and volumes(s) Price(s) Volume(s) GBPNil Cost 2,335 ---------------------------------- ---------------------- ---------------- d) Aggregated information * Aggregate volume N/A * Price * Total ---------------------------------- ---------------------------------------- e) Date of the transaction 2024.01.15 ---------------------------------- ---------------------------------------- f) Place of the transaction Outside a trading venue ---------------------------------- ---------------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Paul Sandland ---------------------------------- ---------------------------------------- 2. Reason for the notification ---------------------------------------------------------------------------- a) Position/status Director/PDMR ---------------------------------- ---------------------------------------- b) Initial notification/ Initial Notification amendment ---------------------------------- ---------------------------------------- 3. Details of the Issuer ---------------------------------------------------------------------------- a) Name Dechra Pharmaceuticals PLC ---------------------------------- ---------------------------------------- b) LEI code 213800J4UVB5OWG8VX82 ---------------------------------- ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------------------- a) Description of Ordinary Shares of 1 pence each the financial instrument ISIN: GB0009633180 Identification code ---------------------------------- ---------------------------------------- b) Nature of the Acquisition of shares pursuant to the transaction Company's Long Term Incentive Plan ---------------------------------- ---------------------------------------- c) Price(s) and volumes(s) Price(s) Volume(s) GBPNil Cost 8,600 ---------------------------------- ---------------------- ---------------- d) Aggregated information * Aggregate volume N/A * Price * Total ---------------------------------- ---------------------------------------- e) Date of the transaction 2024.01.15 ---------------------------------- ---------------------------------------- f) Place of the transaction Outside a trading venue ---------------------------------- ---------------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Paul Sandland ---------------------------------- ---------------------------------------- 2. Reason for the notification ---------------------------------------------------------------------------- a) Position/status Director/PDMR ---------------------------------- ---------------------------------------- b) Initial notification/ Initial Notification amendment ---------------------------------- ---------------------------------------- 3. Details of the Issuer ---------------------------------------------------------------------------- a) Name Dechra Pharmaceuticals PLC ---------------------------------- ---------------------------------------- b) LEI code 213800J4UVB5OWG8VX82 ---------------------------------- ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------------------- a) Description of Ordinary Shares of 1 pence each the financial instrument ISIN: GB0009633180 Identification code ---------------------------------- ---------------------------------------- b) Nature of the Acquisition of shares pursuant to the transaction Company's Long Term Incentive Plan ---------------------------------- ---------------------------------------- c) Price(s) and volumes(s) Price(s) Volume(s) GBPNil Cost 9,983 ---------------------------------- ---------------------- ---------------- d) Aggregated information * Aggregate volume N/A * Price * Total ---------------------------------- ---------------------------------------- e) Date of the transaction 2024.01.15 ---------------------------------- ---------------------------------------- f) Place of the transaction Outside a trading venue ---------------------------------- ---------------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Paul Sandland ------------------------------------ ---------------------------------------- 2. Reason for the notification ------------------------------------------------------------------------------ a) Position/status Director/PDMR ------------------------------------ ---------------------------------------- b) Initial notification/ Initial Notification amendment ------------------------------------ ---------------------------------------- 3. Details of the Issuer ------------------------------------------------------------------------------ a) Name Dechra Pharmaceuticals PLC ------------------------------------ ---------------------------------------- b) LEI code 213800J4UVB5OWG8VX82 ------------------------------------ ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------------------ a) Description of Ordinary Shares of 1 pence each the financial instrument
ISIN: GB0009633180 Identification code ------------------------------------ ---------------------------------------- b) Nature of the Acquisition of shares pursuant to the transaction Company's Long Term Incentive Plan ------------------------------------ ---------------------------------------- c) Price(s) and volumes(s) Price(s) Volume(s) GBP31.99 227 ------------------------------------ ------------------- ------------------- d) Aggregated information * Aggregate volume 227 GBP31.99 * Price GBP7,261.73 * Total ------------------------------------ ---------------------------------------- e) Date of the transaction 2024.01.15 ------------------------------------ ---------------------------------------- f) Place of the transaction Outside a trading venue ------------------------------------ ---------------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Paul Sandland ---------------------------------- ---------------------------------------- 2. Reason for the notification ---------------------------------------------------------------------------- a) Position/status Director/PDMR ---------------------------------- ---------------------------------------- b) Initial notification/ Initial Notification amendment ---------------------------------- ---------------------------------------- 3. Details of the Issuer ---------------------------------------------------------------------------- a) Name Dechra Pharmaceuticals PLC ---------------------------------- ---------------------------------------- b) LEI code 213800J4UVB5OWG8VX82 ---------------------------------- ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------------------- a) Description of Ordinary Shares of 1 pence each the financial instrument ISIN: GB0009633180 Identification code ---------------------------------- ---------------------------------------- b) Nature of the Acquisition of shares pursuant to the transaction Company's Deferred Bonus Plan ---------------------------------- ---------------------------------------- c) Price(s) and volumes(s) Price(s) Volume(s) GBPNil Cost 2,293 ---------------------------------- ---------------------- ---------------- d) Aggregated information * Aggregate volume N/A * Price * Total ---------------------------------- ---------------------------------------- e) Date of the transaction 2024.01.15 ---------------------------------- ---------------------------------------- f) Place of the transaction Outside a trading venue ---------------------------------- ---------------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Paul Sandland ------------------------------------ ------------------------------------------ 2. Reason for the notification -------------------------------------------------------------------------------- a) Position/status Director/PDMR ------------------------------------ ------------------------------------------ b) Initial notification/ Initial Notification amendment ------------------------------------ ------------------------------------------ 3. Details of the Issuer -------------------------------------------------------------------------------- a) Name Dechra Pharmaceuticals PLC ------------------------------------ ------------------------------------------ b) LEI code 213800J4UVB5OWG8VX82 ------------------------------------ ------------------------------------------ 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted -------------------------------------------------------------------------------- a) Description of Ordinary Shares of 1 pence each the financial instrument ISIN: GB0009633180 Identification code ------------------------------------ ------------------------------------------ b) Nature of the Acquisition of shares pursuant to the transaction Company's Global Save As You Earn Plan ------------------------------------ ------------------------------------------ c) Price(s) and volumes(s) Price(s) Volume(s) GBP28.68 627 ------------------------------------ -------------------- -------------------- d) Aggregated information * Aggregate volume 627 GBP28.68 * Price GBP17,982.36 * Total ------------------------------------ ------------------------------------------ e) Date of the transaction 2024.01.15 ------------------------------------ ------------------------------------------ f) Place of the transaction Outside a trading venue ------------------------------------ ------------------------------------------
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBLGDBUSBDGSU
(END) Dow Jones Newswires
January 15, 2024 11:51 ET (16:51 GMT)
1 Year Dechra Pharmaceuticals Chart |
1 Month Dechra Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions